The study analyzed that the IgAnephropathy pipeline comprises of 12 drug candidates in different stages
of development. IgA nephropathy, also known as Berger’s disease, is a kidney
disorder that occurs when IgA antibody gets settled in the kidneys. This leads
to inflammation that with time hinders the kidney’s ability to filter wastes
from blood.
IgA nephropathy is a silent disease
in its early stages with no symptoms. But the most common symptoms that are
usually observed are proteinuria and hematuria. IgA nephropathy does not have a
specific treatment, and the only treatment available is to delay or prevent end
stage renal disease (ESRD). Therefore, combination therapies are being used to
slow down the rate of proteinuria and hematuria and the use of various targets
including a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator
(BlyS) is expected to provide an effective and concrete treatment for the
disease, with latest technological advancements further adding to the pipeline
growth.
Download Report
Sample at: https://www.psmarketresearch.com/market-analysis/iga-nephropathy-pipeline-analysis/report-sample
